[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657942":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":23,"interventions":36,"overallOfficials":46,"centralContacts":13,"locations":13,"responsibleParty":50,"collaborators":13,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":13,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":13,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":13,"overallStatus":72,"whyStopped":13,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":13},{"fullName":5,"class":6},"University of Florida","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Improvement of Los Angeles (LA) classification of Erosive Esphagitis (EE) grade","Assessment of erosive esophagitis grade to determine healing in both arms. Healing would be measured by endoscopic regression of errosive esophagitis (EE) to a lower degree of inflammation. Previously assigned baseline numerical values per the LA classification of EE will be used to calculate the degree of healing in each arm at the 8th week follow up, e.g. LA grade D (initial EGD) to LA grade A (repeat EGD) would yield a score of 3 (LA D \\[5\\] - LA A \\[2\\]). A higher score hence indicating superior healing of EE.","8 weeks",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"DOUBLE",[21,22],"PARTICIPANT","CARE_PROVIDER",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"Intervention","EXPERIMENTAL","proton pump inhibitor dose based on CYP2C19 phenotypes",[29],"Drug: CYP2C19 based dosing Proton Pump Inhibitors",{"label":31,"type":32,"description":33,"interventionNames":34},"Control","ACTIVE_COMPARATOR","conventional proton pump inhibitor dose of Pantoprazole 40 mg once or twice daily",[35],"Drug: Conventional proton pump inhibitor dose",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":13},"DRUG","CYP2C19 based dosing Proton Pump Inhibitors","Pantoprazole dosing based on CYP2C19 phenotypes",[25],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":13},"Conventional proton pump inhibitor dose","conventional PPI dose of Pantoprazole 40 mg once or twice daily",[31],[47],{"name":48,"affiliation":5,"role":49},"Ruchir Puri, MD","PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100657942","phase-4-ppi-dosing-per-cyp2c19-genotype-100657942",false,"NCT07843264","PPI Dosing Per CYP2C19 Genotype","A Pilot Study to Assess Healing of Erosive Esophagitis in Patients Randomized to Conventional PPI Doses Versus Dosing Based on CYP2C19 Genotype","Inclusion Criteria:\n\n* age ≥ 18 years\n* diagnosis of Gastroesophageal Reflux Disease (GERD) scheduled for an esophagogastroduodenoscopy (EGD)\n* patients diagnosed with Erosive Esophagitis on endoscopy (EGD).\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* diagnosed with non-erosive reflux disease (NERD)\n* pregnancy",true,"ALL","18 Years","90 Years",{"count":64,"type":65},200,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.",[71],"Gastroesophageal Reflux Disease With Esophagitis","NOT_YET_RECRUITING","2026-09-23",{"date":75,"type":76},"2026-09-28","ACTUAL",{"date":78,"type":65},"2026-10",{"date":80,"type":65},"2028-04-01",{"name":5,"class":6}]